SEC Form 4 · accession 0001077183-19-000025
NEOGENOMICS INC · NEO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lawrence Martin Weiss
Officer — Chief Scientific Officer
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 4:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001077183
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 1, 2019 | A | 5,893 | $0.00 | A | 5,893 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $19.60 | Mar 1, 2019 | A | 36,022 | A | Mar 1, 2020 | Mar 1, 2024 | Common Stock | 36,022 | 36,022 | D |
| Stock Option (Right to Buy)F2 | $13.87 | holding | — | — | — | Dec 12, 2019 | Dec 12, 2023 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1On March 1, 2019, Dr. Weiss was granted an option to purchase shares of NeoGenomics, Inc. common stock. The option vests ratably over the first four anniversary dates of the grant date.
- F2On December 12, 2018, Dr. Weiss was granted an option to purchase shares of NeoGenomics, Inc. common stock. The option vests ratably over the first three anniversary dates of the grant date.